Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2017: 3.556

CiteScore 2017: 2.34

SCImago Journal Rank (SJR) 2017: 1.114
Source Normalized Impact per Paper (SNIP) 2017: 1.188

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 53, Issue 1

Issues

Serum fucosylated haptoglobin in chronic liver diseases as a potential biomarker of hepatocellular carcinoma development

Hitomi Asazawa
  • Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Osaka, Japan
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Yoshihiro Kamada
  • Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Osaka, Japan
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Yuri Takeda
  • Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Osaka, Japan
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Shinji Takamatsu
  • Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Osaka, Japan
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Shinichiro Shinzaki
  • Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Osaka, Japan
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Youkoku Kim / Riichiro Nezu / Noriyoshi Kuzushita / Eiji Mita / Michio Kato / Eiji Miyoshi
  • Corresponding author
  • Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Osaka, Japan
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2014-07-23 | DOI: https://doi.org/10.1515/cclm-2014-0427

Abstract

Background: Fucosylation is one of the most important glycosylation events involved in cancer and inflammation. We previously developed a lectin antibody ELISA kit to measure fucosylated haptoglobin (Fuc-Hpt), which we identified as a novel cancer biomarker. In this study, we investigated Fuc-Hpt as a biomarker in chronic liver diseases, especially in hepatocellular carcinoma (HCC).

Methods: We measured serum Fuc-Hpt levels using our ELISA kit in 318 patients with chronic liver diseases, including 145 chronic hepatitis (CH) patients, 81 liver cirrhosis (LC) patients, and 92 HCC patients. During a long-term follow-up period of 7 years (1996–2003), Fuc-Hpt levels were measured at three different time points in 19 HCC patients. Serum Fuc-Hpt levels were also examined with a short-term follow-up period of 3 years (2009–2012) in 13 HCC patients.

Results: Fuc-Hpt levels increased with liver disease progression. Patients with LC and HCC showed significantly increased Fuc-Hpt levels in comparison to CH patients or healthy volunteers. Fuc-Hpt levels tended to be higher in HCC patients than in LC patients. Fuc-Hpt was better than α-fetoprotein (AFP) and AFP-L3 for predicting HCC [diagnosed by computed tomography (CT) or ultrasound] in LC patients with long-term follow-up. More than 80% of LC patients with long-term follow-up showed increased Fuc-Hpt during hepatocarcinogenesis, and 38% of early-stage HCC patients with short-term follow-up showed a gradual increase in Fuc-Hpt before imaging diagnosis.

Conclusions: These results suggest that Fuc-Hpt is a novel and potentially useful biomarker for predicting liver disease progression and HCC development.

This article offers supplementary material which is provided at the end of the article.

Keywords: α-fetoprotein (AFP); fucosylation; lectin antibody ELISA kit; protein induced by vitamin K antagonist II (PIVKA-II)

References

  • 1.

    Miyoshi E, Moriwaki K, Nakagawa T. Biological function of fucosylation in cancer biology. J Biochem 2008;143:725–9.Web of ScienceGoogle Scholar

  • 2.

    Wang M, Long RE, Comunale MA, Junaidi O, Marrero J, Di Bisceglie AM, et al. Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2009;18:1914–21.CrossrefWeb of ScienceGoogle Scholar

  • 3.

    Hashimoto S, Asao T, Takahashi J, Yagihashi Y, Nishimura T, Saniabadi AR, et al. alpha1-acid glycoprotein fucosylation as a marker of carcinoma progression and prognosis. Cancer 2004;101:2825–36.Google Scholar

  • 4.

    Debruyne EN, Vanderschaeghe D, Van Vlierberghe H, Vanhecke A, Callewaert N, Delanghe JR. Diagnostic value of the hemopexin N-glycan profile in hepatocellular carcinoma patients. Clin Chem 2010;56:823–31.Web of ScienceGoogle Scholar

  • 5.

    Taketa K. Alpha-fetoprotein: reevaluation in hepatology. Hepatology 1990;12:1420–32.PubMedCrossrefGoogle Scholar

  • 6.

    Breborowicz J, Mackiewicz A, Breborowicz D. Microheterogeneity of alpha-fetoprotein in patient serum as demonstrated by lectin affino-electrophoresis. Scand J Immunol 1981;14:15–20.PubMedCrossrefGoogle Scholar

  • 7.

    Taketa K, Izumi M, Ichikawa E. Distinct molecular species of human alpha-fetoprotein due to differential affinities to lectins. Ann N Y Acad Sci 1983;417:61–8.Google Scholar

  • 8.

    Aoyagi Y. Carbohydrate-based measurements on alpha-fetoprotein in the early diagnosis of hepatocellular carcinoma. Glycoconj J 1995;12:194–9.PubMedGoogle Scholar

  • 9.

    Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009;137:110–8.Google Scholar

  • 10.

    Okuyama N, Ide Y, Nakano M, Nakagawa T, Yamanaka K, Moriwaki K, et al. Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int J Cancer 2006;118:2803–8.Google Scholar

  • 11.

    Nakano M, Nakagawa T, Ito T, Kitada T, Hijioka T, Kasahara A, et al. Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers. Int J Cancer 2008;122:2301–9.Google Scholar

  • 12.

    Takeda Y, Shinzaki S, Okudo K, Moriwaki K, Murata K, Miyoshi E. Fucosylated haptoglobin is a novel type of cancer biomarker linked to the prognosis after an operation in colorectal cancer. Cancer 2012;118:3036–43.Google Scholar

  • 13.

    Narisada M, Kawamoto S, Kuwamoto K, Moriwaki K, Nakagawa T, Matsumoto H, et al. Identification of an inducible factor secreted by pancreatic cancer cell lines that stimulates the production of fucosylated haptoglobin in hepatoma cells. Biochem Biophys Res Commun 2008;377:792–6.Web of ScienceGoogle Scholar

  • 14.

    Matsumoto H, Shinzaki S, Narisada M, Kawamoto S, Kuwamoto K, Moriwaki K, et al. Clinical application of a lectin-antibody ELISA to measure fucosylated haptoglobin in sera of patients with pancreatic cancer. Clin Chem Lab Med 2010;48:505–12.Web of ScienceGoogle Scholar

  • 15.

    Kormoczi GF, Saemann MD, Buchta C, Peck-Radosavljevic M, Mayr WR, Schwartz DW, et al. Influence of clinical factors on the haemolysis marker haptoglobin. Eur J Clin Invest 2006;36: 202–9.Google Scholar

  • 16.

    Kamada Y, Kinoshita N, Tsuchiya Y, Kobayashi K, Fujii H, Terao N, et al. Reevaluation of a lectin antibody ELISA kit for measuring fucosylated haptoglobin in various conditions. Clin Chim Acta 2013;417:48–53.Web of ScienceGoogle Scholar

  • 17.

    Kagebayashi C, Yamaguchi I, Akinaga A, Kitano H, Yokoyama K, Satomura M, et al. Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis. Anal Biochem 2009;388:306–11.Web of ScienceGoogle Scholar

  • 18.

    Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289–93.Google Scholar

  • 19.

    Nakagawa T, Uozumi N, Nakano M, Mizuno-Horikawa Y, Okuyama N, Taguchi T, et al. Fucosylation of N-glycans regulates the secretion of hepatic glycoproteins into bile ducts. J Biol Chem 2006;281:29797–806.Google Scholar

  • 20.

    Nakagawa T, Takeishi S, Kameyama A, Yagi H, Yoshioka T, Moriwaki K, et al. Glycomic analyses of glycoproteins in bile and serum during rat hepatocarcinogenesis. J Proteome Res 2010;9:4888–96.Web of ScienceCrossrefGoogle Scholar

About the article

Corresponding author: Eiji Miyoshi, MD, PhD, Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, 1-7, Yamada-oka, Suita, Osaka 565-0871, Japan, Phone/Fax: +81 6 68792590, E-mail:

aHitomi Asazawa and Yoshihiro Kamada contributed equally to this study.


Received: 2014-04-19

Accepted: 2014-06-30

Published Online: 2014-07-23

Published in Print: 2015-01-01


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 53, Issue 1, Pages 95–102, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2014-0427.

Export Citation

©2015 by De Gruyter.Get Permission

Supplementary Article Materials

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[2]
Antônia S F do Nascimento, Sonia Serna, Ana Beloqui, Ana Arda, Alexandre H Sampaio, Janika Walcher, Dimitri Ott, Carlo Unverzagt, Niels-Christian Reichardt, Jesus Jimenez-Barbero, Kyria S Nascimento, Anne Imberty, Benildo S Cavada, and Annabelle Varrot
Glycobiology, 2015, Volume 25, Number 6, Page 607
[3]
Anna Drabik, Anna Bodzon-Kulakowska, Piotr Suder, Jerzy Silberring, Jan Kulig, and Marek Sierzega
Journal of Proteome Research, 2017, Volume 16, Number 4, Page 1436
[4]
Eva Åström, Per Stål, Robin Zenlander, Pia Edenvik, Catharina Alexandersson, Mats Haglund, Ingvar Rydén, Peter Påhlsson, and Anand S Mehta
PLOS ONE, 2017, Volume 12, Number 3, Page e0173897
[5]
Seiichi Tawara, Tomohide Tatsumi, Sadaharu Iio, Ichizou Kobayashi, Minoru Shigekawa, Hayato Hikita, Ryotaro Sakamori, Naoki Hiramatsu, Eiji Miyoshi, Tetsuo Takehara, and Ranjit Ray
PLOS ONE, 2016, Volume 11, Number 3, Page e0151828
[6]
Atsuko Sawanobori, Kenta Moriwaki, Shinji Takamatsu, Yoshihiro Kamada, and Eiji Miyoshi
PROTEOMICS, 2016, Volume 16, Number 24, Page 3073
[7]
Ya-Xuan Wang, Jin-Xing Liu, Ying-Lian Gao, Chun-Hou Zheng, and Jun-Liang Shang
Computational Biology and Chemistry, 2016, Volume 65, Page 185
[8]
Eun Sun Ji, Heeyoun Hwang, Gun Wook Park, Ju Yeon Lee, Hyun Kyoung Lee, Na Young Choi, Hoi Keun Jeong, Kwang Hoe Kim, Jin Young Kim, Seungho Lee, Yeong Hee Ahn, and Jong Shin Yoo
Analytical and Bioanalytical Chemistry, 2016, Volume 408, Number 27, Page 7761
[9]
Shu Zhang, Shuxin Shang, Wei Li, Xue Qin, and Yinkun Liu
Glycobiology, 2016, Volume 26, Number 7, Page 684
[10]
Junichi Seino, Haruhiko Fujihira, Shin-ichi Nakakita, Yuki Masahara-Negishi, Eiji Miyoshi, Jun Hirabayashi, and Tadashi Suzuki
Glycobiology, 2016, Volume 26, Number 10, Page 1072
[11]
Julio César Villegas-Pineda, Olga Lilia Garibay-Cerdenares, Verónica Ivonne Hernández-Ramírez, Dolores Gallardo-Rincón, David Cantú de León, María Delia Pérez-Montiel-Gómez, and Patricia Talamás-Rohana
Pathology - Research and Practice, 2015, Volume 211, Number 12, Page 973
[12]
Kai Jiang, Shuxin Shang, Wei Li, Kun Guo, Xue Qin, Shu Zhang, and Yinkun Liu
Glycoconjugate Journal, 2015, Volume 32, Number 9, Page 657
[13]
Abolfazl Pourhassan, Daniel Fadaei Fouladi, Simin Mirakhor Samani, and Sam Morshedi Asl
Biological Trace Element Research, 2015, Volume 167, Number 2, Page 187

Comments (0)

Please log in or register to comment.
Log in